A Court hearing to decide whether non US residents will be able to take legal action in the US over the drug Vioxx will be held next month.
Merck are challenging the right of UK citizens to take legal action in the US over Vioxx.
On the 31st March a Judge will decide whether UK citizens have the right to take legal action in the US.
This will give the go-ahead to a number of UK law firms, all planning to instruct lawyers in the US to sue the pharmaceutical giant over use of the stroke drug.
Alexander Harris act for over seventy UK citizens harmed as a result of taking the withdrawn drug Vioxx.
We have issued over 20 cases in the US state of New Jersey and have a further 50 waiting in the wings.
Used as a painkiller for conditions such as osteoarthritis and rheumatoid arthritis, Vioxx was withdrawn by pharmaceutical giant Merck in September 2004 due to concerns over its safety.
"We took the decision to bring these cases in the States as we believe that this is in the best interests of our clients. We may not be able to pursue the claims to conclusion if we fail on what is known as the forum argument. This decides whether you are allowed to bring a case in a different country to your own. It will be a decision for the Judge as to whether non US residents will be allowed to pursue their claims in the US court," said Ann Alexander.
We have received over 600 enquiries from people who believe they have suffered as a result of taking Vioxx.
Background
Merck pulled Vioxx, a $2.5 billion seller, from the market in September 2004 when a long-term study showed it could double risk of heart attack or stroke if taken for 18 months or longer.
Vioxx inhibits an enzyme known as Cox-2, which thins the blood. That feature allows it and other drugs in its class - Pfizer's Bextra and Celebrex - to relieve acute pain and arthritis without causing stomach bleeds or ulcers, as painkillers such as aspirin can.
An FDA panel concluded in February that Vioxx, Celebrexand Bextra all pose heart risks but should be available to consumers. But in April, Pfizer withdrew Bextra from the market at the FDA's request when the agency said it carries risk of serious and sometimes fatal skin reactions in addition to heart attacks and strokes.
The FDA also said that all prescription non steroidal, anti-inflammatory drugs, not just Cox-2 inhibitors, should carry a so-called ''black box'' warning label about cardiovascular risk.
Related news stories
- 18/08/2006: MERCK ORDERED TO PAY COMPENSATION TO VIOXX USER
- 11/04/2006: Judge to rule on whether UK citizens can make vioxx claims in the US
- 31/03/2006: Vioxx Hearing - Judge to rule on whether UK citizens can make Vioxx claims in the US
- 13/12/2005: First vioxx lawsuit declared a mistrial
- 22/08/2005: First UK Vioxx case filed in the USA
- 10/06/2005: Ibuprofen carries higher risk of heart attack than cox-2 drug celecoxib
- 08/06/2005: Care given to patients after heart attacks is not good enough
- 12/04/2005: Bextra - Cox-2 drug withdrawn over skin concerns
- 21/02/2005: FDA votes to re-instate Vioxx in US
If you believe that you might have a legal claim relating to this story, please complete the online enquiry form or call 0870 024 0558. Your enquiry will be forwarded to a solicitor who specialises in this area.
If you have any comments in relation to this story, please use the online discussion forum.
This news section contains stories of interest to our clients from publicly available news sources. Where we are representing the clients referred to in the news material we will say so. Where we do not represent individuals or bodies mentioned or quoted, the inclusion of the news story in our news section is not intended nor should it be taken to imply that we act for the individual or body concerned.
I am grateful for the manner and conduct of your involvement and the tactful approach: Kenneth, Sevenoaks
